Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
206 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Diabetic Nephropathy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Diabetic Nephropathy - Pipeline Review, H2 2014', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Diabetic Nephropathy Overview 9 Therapeutics Development 10 Pipeline Products for Diabetic Nephropathy - Overview 10 Pipeline Products for Diabetic Nephropathy - Comparative Analysis 11 Diabetic Nephropathy - Therapeutics under Development by Companies 12 Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes 16 Diabetic Nephropathy - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Diabetic Nephropathy - Products under Development by Companies 21 Diabetic Nephropathy - Products under Investigation by Universities/Institutes 24 Diabetic Nephropathy - Companies Involved in Therapeutics Development 25 Bristol-Myers Squibb Company 25 Johnson & Johnson 26 Sanofi 27 AstraZeneca PLC 28 Eli Lilly and Company 29 GlaxoSmithKline plc 30 Gilead Sciences, Inc. 31 Daiichi Sankyo Company, Limited 32 Astellas Pharma Inc. 33 Chong Kun Dang Pharmaceutical Corp. 34 InterMune, Inc. 35 Mitsubishi Tanabe Pharma Corporation 36 Pfizer Inc. 37 NephroGenex, Inc. 38 Shire Plc 39 Bayer AG 40 Mesoblast Limited 41 Jazz Pharmaceuticals plc 42 Torrent Pharmaceuticals Limited 43 Dong Wha Pharma Co., Ltd. 44 Galectin Therapeutics, Inc. 45 PhytoHealth Corporation 46 DiaMedica Inc. 47 Angelini Group 48 IMMD Inc. 49 GenKyoTex S.A. 50 Concert Pharmaceuticals, Inc. 51 Noxxon Pharma AG 52 Intercept Pharmaceuticals, Inc. 53 Omeros Corporation 54 ChemoCentryx, Inc. 55 Glucox Biotech AB 56 GNI Group Ltd. 57 OncoImmune, Inc. 58 Cellmid Limited 59 Serodus ASA 60 Islet Sciences, Inc. 61 AbbVie Inc. 62 Inventiva SAS 63 Mallinckrodt plc 64 Diabetic Nephropathy - Therapeutics Assessment 65 Assessment by Monotherapy Products 65 Assessment by Target 66 Assessment by Mechanism of Action 70 Assessment by Route of Administration 74 Assessment by Molecule Type 76 Drug Profiles 78 canagliflozin - Drug Profile 78 atrasentan hydrochloride - Drug Profile 80 Pyridoxamine Dihydrochloride - Drug Profile 81 pirfenidone - Drug Profile 82 baricitinib - Drug Profile 84 SER-150 - Drug Profile 86 emapticap pegol - Drug Profile 87 IMD-1041 - Drug Profile 89 CS-3150 - Drug Profile 90 DW-1029M - Drug Profile 91 GKT-137831 - Drug Profile 92 PF-00489791 - Drug Profile 93 CCX-140 - Drug Profile 94 bindarit - Drug Profile 96 probucol - Drug Profile 98 PF-04634817 - Drug Profile 99 GLY-230 - Drug Profile 100 corticotropin - Drug Profile 102 BMS-813160 - Drug Profile 104 CTP-499 - Drug Profile 105 MT-3995 - Drug Profile 107 finerenone - Drug Profile 108 PHN-033 - Drug Profile 109 CKD-322 - Drug Profile 110 Allogeneic Mesenchymal Precursor Cells for Diabetic Nephropathy - Drug Profile 111 GS-4997 - Drug Profile 113 Small Molecule to Inhibit Xanthine Oxidase for Diabetic Nephropathy - Drug Profile 114 DM-199 - Drug Profile 115 MT-3995 - Drug Profile 117 SHP-627 - Drug Profile 118 ASP-8232 - Drug Profile 119 ASP-7657 - Drug Profile 120 pirfenidone - Drug Profile 121 DT-23552 - Drug Profile 122 INT-767 - Drug Profile 123 A-717 - Drug Profile 125 GR-MD-02 - Drug Profile 126 hu-91 - Drug Profile 128 Oligotide - Drug Profile 130 GKT-136901 - Drug Profile 132 Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 134 Cyndacel-M - Drug Profile 135 Monoclonal Antibody to Target HPTPbeta for Diabetic Nephropathy - Drug Profile 136 Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders - Drug Profile 137 Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 138 MG-132 - Drug Profile 139 GW-610742 - Drug Profile 140 TRC-120038 - Drug Profile 142 JNJ-39933673 - Drug Profile 143 11-RVIVIT - Drug Profile 144 Nephrilin - Drug Profile 145 DCB-DN1 - Drug Profile 146 Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 147 SP-20202 - Drug Profile 149 OX-029 - Drug Profile 150 Drug for Diabetic Nephropathy - Drug Profile 151 Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile 152 Small Molecules for Diabetic Nephropathy - Drug Profile 153 Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 154 NP-04 - Drug Profile 156 Small Molecules for Diabetic Nephropathy - Drug Profile 157 Diabetic Nephropathy - Recent Pipeline Updates 158 Diabetic Nephropathy - Dormant Projects 191 Diabetic Nephropathy - Discontinued Products 192 Diabetic Nephropathy - Product Development Milestones 193 Featured News & Press Releases 193 Appendix 201 Methodology 201 Coverage 201 Secondary Research 201 Primary Research 201 Expert Panel Validation 201 Contact Us 202 Disclaimer 202
List of Tables Number of Products under Development for Diabetic Nephropathy, H2 2014 14 Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2014 20 Comparative Analysis by Late Stage Development, H2 2014 21 Comparative Analysis by Clinical Stage Development, H2 2014 22 Comparative Analysis by Early Stage Development, H2 2014 23 Comparative Analysis by Unknown Stage Development, H2 2014 24 Products under Development by Companies, H2 2014 25 Products under Development by Companies, H2 2014 (Contd..1) 26 Products under Development by Companies, H2 2014 (Contd..2) 27 Products under Investigation by Universities/Institutes, H2 2014 28 Diabetic Nephropathy - Pipeline by Bristol-Myers Squibb Company, H2 2014 29 Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2014 30 Diabetic Nephropathy - Pipeline by Sanofi, H2 2014 31 Diabetic Nephropathy - Pipeline by AstraZeneca PLC, H2 2014 32 Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H2 2014 33 Diabetic Nephropathy - Pipeline by GlaxoSmithKline plc, H2 2014 34 Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H2 2014 35 Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 36 Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H2 2014 37 Diabetic Nephropathy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 38 Diabetic Nephropathy - Pipeline by InterMune, Inc., H2 2014 39 Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 40 Diabetic Nephropathy - Pipeline by Pfizer Inc., H2 2014 41 Diabetic Nephropathy - Pipeline by NephroGenex, Inc., H2 2014 42 Diabetic Nephropathy - Pipeline by Shire Plc, H2 2014 43 Diabetic Nephropathy - Pipeline by Bayer AG, H2 2014 44 Diabetic Nephropathy - Pipeline by Mesoblast Limited, H2 2014 45 Diabetic Nephropathy - Pipeline by Jazz Pharmaceuticals plc, H2 2014 46 Diabetic Nephropathy - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 47 Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H2 2014 48 Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H2 2014 49 Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H2 2014 50 Diabetic Nephropathy - Pipeline by DiaMedica Inc., H2 2014 51 Diabetic Nephropathy - Pipeline by Angelini Group, H2 2014 52 Diabetic Nephropathy - Pipeline by IMMD Inc., H2 2014 53 Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H2 2014 54 Diabetic Nephropathy - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 55 Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2014 56 Diabetic Nephropathy - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014 57 Diabetic Nephropathy - Pipeline by Omeros Corporation, H2 2014 58 Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H2 2014 59 Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H2 2014 60 Diabetic Nephropathy - Pipeline by GNI Group Ltd., H2 2014 61 Diabetic Nephropathy - Pipeline by OncoImmune, Inc., H2 2014 62 Diabetic Nephropathy - Pipeline by Cellmid Limited, H2 2014 63 Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2014 64 Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H2 2014 65 Diabetic Nephropathy - Pipeline by AbbVie Inc., H2 2014 66 Diabetic Nephropathy - Pipeline by Inventiva SAS, H2 2014 67 Diabetic Nephropathy - Pipeline by Mallinckrodt plc, H2 2014 68 Assessment by Monotherapy Products, H2 2014 69 Number of Products by Stage and Target, H2 2014 72 Number of Products by Stage and Mechanism of Action, H2 2014 76 Number of Products by Stage and Route of Administration, H2 2014 79 Number of Products by Stage and Molecule Type, H2 2014 81 Diabetic Nephropathy Therapeutics - Recent Pipeline Updates, H2 2014 162 Diabetic Nephropathy - Dormant Projects, H2 2014 195 Diabetic Nephropathy - Discontinued Products, H2 2014 196
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
